~~<i id='2C8E4DB6BC'><strike id='2C8E4DB6BC'><tt id='2C8E4DB6BC'><pre id='2C8E4DB6BC'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：Wikipedia 2025-09-27 09:08:42 Page View：23951

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Unmasking the 'centricity' illusion in clinical trials
Next article： Novavax promises a turnaround & Lilly roils the obesity market

focus

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Congress: Prevent baby formula shortages by passing a new bill

ScottOlson/GettyImagesFamiliesinAmericashouldneverhavetoscroungeforbabyformula.TheUnitedStatesneedsa

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Achieving telehealth equity for people with hearing loss

AdobeGenZhasmadecaptioningcool.Captionsarenowwidelyavailableinsocialmedia,entertainmentchannels,andw